Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium
Author:
Publisher
Elsevier BV
Subject
Pharmacology
Reference15 articles.
1. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence;Arnt;Neuropsychopharmacology,1998
2. Olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial;Beasley;Neuropsychopharmacology,1996
3. The effect of ions on the binding of agonists and antagonists to muscarinic receptors;Birdsall;Br. J. Pharmacol.,1979
4. Radioreceptor binding profile of the atypical antipsychotic olanzapine;Bymaster;Neuropsychopharmacology,1996
5. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro;Bymaster;Schizophr. Res.,1999
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial;The Lancet Oncology;2024-02
2. Investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20): a study protocol for an open-label, single-arm exploratory study;BMJ Open;2024-02
3. The Benefits of Olanzapine in Palliating Symptoms;Current Treatment Options in Oncology;2020-11-26
4. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;The Lancet Oncology;2020-02
5. Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy;Japanese Journal of Clinical Oncology;2018-08-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3